Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Glibenclamide (Primary) ; Alteplase
- Indications Brain oedema; Cerebral infarction; Stroke
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CHARM
- Sponsors Biogen; Remedy Pharmaceuticals
- 26 Oct 2023 This study has been completed in Germany, according to European Clinical Trials Database record.
- 22 Oct 2023 This study has been completed in Czech Republic, according to European Clinical Trials Database record.
- 19 Oct 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.